drug_type
RELEVANT_DRUG
intervention_type
TCR-based bispecific biologic (ImmTAC)
drug_description
A TCR-based bispecific ImmTAC biologic that uses a high-affinity TCR to bind a PIWIL1-derived peptide presented by HLA-A*02:01 on tumor cells and an anti-CD3 domain to recruit/activate T cells; administered IV.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Fusion Proteins, Immunologic
drug_category
BISPECIFIC T ENGAGER
drug_class
Engager
drug_delivery_route
Intravenous
drug_mechanism_of_action
IMC-R117C is a soluble TCR–CD3 bispecific (ImmTAC) that uses an affinity-enhanced TCR to bind a PIWIL1-derived peptide presented by HLA-A*02:01 on tumor cells and an anti-CD3 domain to recruit and activate polyclonal T cells, driving synapse formation, cytokine release, and targeted T‑cell cytotoxicity against PIWIL1+ HLA-A*02:01 tumor cells.
drug_name
IMC-R117C
nct_id_drug_ref
NCT06840119